
Janice E. Seeger
Examiner (ID: 5162)
| Most Active Art Unit | 2913 |
| Art Unit(s) | 2913, 0, 2903, 2900 |
| Total Applications | 6758 |
| Issued Applications | 6653 |
| Pending Applications | 0 |
| Abandoned Applications | 105 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17441784
[patent_doc_number] => 20220062289
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => Nucleotide Analogs
[patent_app_type] => utility
[patent_app_number] => 17/524334
[patent_app_country] => US
[patent_app_date] => 2021-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17524334
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/524334 | Nucleotide analogs | Nov 10, 2021 | Issued |
Array
(
[id] => 17458700
[patent_doc_number] => 20220072004
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => Nucleotide Analogs
[patent_app_type] => utility
[patent_app_number] => 17/523806
[patent_app_country] => US
[patent_app_date] => 2021-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21197
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17523806
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/523806 | Nucleotide analogs | Nov 9, 2021 | Issued |
Array
(
[id] => 17441919
[patent_doc_number] => 20220062424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => PRESERVATIVE CONTAINING COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/522171
[patent_app_country] => US
[patent_app_date] => 2021-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19889
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522171
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/522171 | PRESERVATIVE CONTAINING COMPOSITIONS | Nov 8, 2021 | Pending |
Array
(
[id] => 17633806
[patent_doc_number] => 11344510
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-31
[patent_title] => Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
[patent_app_type] => utility
[patent_app_number] => 17/510108
[patent_app_country] => US
[patent_app_date] => 2021-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 49953
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17510108
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/510108 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | Oct 24, 2021 | Issued |
Array
(
[id] => 17426789
[patent_doc_number] => 20220054497
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/508202
[patent_app_country] => US
[patent_app_date] => 2021-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5043
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17508202
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/508202 | PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS | Oct 21, 2021 | Abandoned |
Array
(
[id] => 17519182
[patent_doc_number] => 20220105030
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => INTRANASAL DELIVERY OF DIHYDROERGOTAMINE BY PRECISION OLFACTORY DEVICE
[patent_app_type] => utility
[patent_app_number] => 17/492136
[patent_app_country] => US
[patent_app_date] => 2021-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13541
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17492136
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/492136 | INTRANASAL DELIVERY OF DIHYDROERGOTAMINE BY PRECISION OLFACTORY DEVICE | Sep 30, 2021 | Abandoned |
Array
(
[id] => 17480515
[patent_doc_number] => 20220088019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => PAC-1 COMBINATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/487473
[patent_app_country] => US
[patent_app_date] => 2021-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18246
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17487473
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/487473 | PAC-1 combination therapy | Sep 27, 2021 | Issued |
Array
(
[id] => 18238666
[patent_doc_number] => 20230070977
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => CONTRACEPTIVE REGIMEN INCLUDING REDUCED LEVEL OF ESTROGEN
[patent_app_type] => utility
[patent_app_number] => 17/483199
[patent_app_country] => US
[patent_app_date] => 2021-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8873
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17483199
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/483199 | Contraceptive regimen including reduced level of estrogen | Sep 22, 2021 | Issued |
Array
(
[id] => 20491461
[patent_doc_number] => 12533316
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-27
[patent_title] => Parenteral dosage form of amiodarone
[patent_app_type] => utility
[patent_app_number] => 17/447748
[patent_app_country] => US
[patent_app_date] => 2021-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 719
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17447748
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/447748 | Parenteral dosage form of amiodarone | Sep 14, 2021 | Issued |
Array
(
[id] => 18266564
[patent_doc_number] => 20230087806
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => METHODS OF USING EHMT2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/474581
[patent_app_country] => US
[patent_app_date] => 2021-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36653
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17474581
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/474581 | METHODS OF USING EHMT2 INHIBITORS | Sep 13, 2021 | Abandoned |
Array
(
[id] => 17880378
[patent_doc_number] => 20220295855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => Methods and Compositions for Slowing an Aging Process in a Human or an Animal
[patent_app_type] => utility
[patent_app_number] => 17/463099
[patent_app_country] => US
[patent_app_date] => 2021-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15766
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 129
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463099
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/463099 | Methods and Compositions for Slowing an Aging Process in a Human or an Animal | Aug 30, 2021 | Pending |
Array
(
[id] => 19503774
[patent_doc_number] => 12115172
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Sulfate-free cleansing composition that confers high salicylic acid deposition
[patent_app_type] => utility
[patent_app_number] => 17/411903
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9927
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 244
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411903
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/411903 | Sulfate-free cleansing composition that confers high salicylic acid deposition | Aug 24, 2021 | Issued |
Array
(
[id] => 19332602
[patent_doc_number] => 20240247032
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE
[patent_app_type] => utility
[patent_app_number] => 18/558364
[patent_app_country] => US
[patent_app_date] => 2021-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 257
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558364
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/558364 | METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE | Aug 22, 2021 | Pending |
Array
(
[id] => 18893717
[patent_doc_number] => 20240009202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => MITOCHONDRIA-TARGETED ANTIOXIDANT AS AGENT FOR TREATING PATHOLOGIC INFLAMMATION CAUSED BY MABC-R INFECTION
[patent_app_type] => utility
[patent_app_number] => 18/042010
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9048
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042010
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/042010 | MITOCHONDRIA-TARGETED ANTIOXIDANT AS AGENT FOR TREATING PATHOLOGIC INFLAMMATION CAUSED BY MABC-R INFECTION | Aug 17, 2021 | Pending |
Array
(
[id] => 17383857
[patent_doc_number] => 20220031709
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => INHIBITION OF MICROSOMAL PROSTAGLANDIN E2 (PGE2) SYNTHASE-1 (MPGES-1)
[patent_app_type] => utility
[patent_app_number] => 17/393210
[patent_app_country] => US
[patent_app_date] => 2021-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393210
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/393210 | INHIBITION OF MICROSOMAL PROSTAGLANDIN E2 (PGE2) SYNTHASE-1 (MPGES-1) | Aug 2, 2021 | Abandoned |
Array
(
[id] => 17198513
[patent_doc_number] => 20210338607
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => MONO- AND DI-AMIDINE ENDO-EXONUCLEASE INHIBITORS AND METHODS FOR INHIBITING ENDO-EXONUCLEASE ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/378346
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10938
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378346
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/378346 | Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity | Jul 15, 2021 | Issued |
Array
(
[id] => 17198738
[patent_doc_number] => 20210338832
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => Long Acting Multi-Specific Molecules And Related Methods
[patent_app_type] => utility
[patent_app_number] => 17/373296
[patent_app_country] => US
[patent_app_date] => 2021-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18732
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373296
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373296 | Long acting multi-specific molecules and related methods | Jul 11, 2021 | Issued |
Array
(
[id] => 17342049
[patent_doc_number] => 20220008380
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => METHODS OF TREATING COVID-19 PATHOGENESIS
[patent_app_type] => utility
[patent_app_number] => 17/368911
[patent_app_country] => US
[patent_app_date] => 2021-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7712
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17368911
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/368911 | METHODS OF TREATING COVID-19 PATHOGENESIS | Jul 6, 2021 | Abandoned |
Array
(
[id] => 17625666
[patent_doc_number] => 20220160681
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
[patent_app_type] => utility
[patent_app_number] => 17/365797
[patent_app_country] => US
[patent_app_date] => 2021-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36920
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365797
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/365797 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Jun 30, 2021 | Abandoned |
Array
(
[id] => 19637402
[patent_doc_number] => 12167998
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-17
[patent_title] => Spiro-lactam NMDA receptor modulators and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/357064
[patent_app_country] => US
[patent_app_date] => 2021-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 33025
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357064
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/357064 | Spiro-lactam NMDA receptor modulators and uses thereof | Jun 23, 2021 | Issued |